CoSyne Therapeutics
Drug discovery company
- 1-20 employees
- Healthcare
- B2B
- Biotechnology
- MedTech
- Soho, London, UK
Jump to section
Company mission
To create new treatments to help patients. Everything else is secondary.
Our take
On a mission to break down barriers between the technology industry and the biological industry in order to push the limits of science, computing and artificial intelligence, Cosyne Therapeutics is a computational drug discovery company that uses genetics and computational systems to develop next-generation medicines.
In its early stages, Cosyne’s primary goal is to build a new class of drugs to treat Glioblastoma Multiforme, which is considered the most deadly form of human brain cancer. It is well placed to do this, as its platform enables the identification of vulnerabilities in cells that no other institution has done before.
The company recently closed a significant seed-funding round from industry-leading investors, which is being used to expand the scope of its functional genomics and machine learning capabilities.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Generous Equity Scheme
- Flexible Working Style
- Enhanced parental leave for primary and secondary caregiver
- More Benefits to come after Series A (We want you to help us design the benefits that work best for you)
Funding (1 round)
Jan 2022
$0.5m
GRANT
Total funding: $0.5m
This company has top investors
Leadership
Liisi Laaniste
(CSO & Founder)Previously spent time as a Post-Doctoral Researcher for Imperial College London and as a Junior Researcher for Uppsala University.
Louwai Muhammed
(CEO & Founder)Previously spent over eight years at the NHS, initially as an Academic Foundation Doctor, and later as a Neurology Registrar.
Michael Johnson
(CMO & Founder)Professor of Neurology and Genomic Medicine.